Amazon's Q4 results were mixed, as AWS is still relatively sluggish versus Google Cloud and Azure. Check out why AMZN stock ...

GigaCloud proves the bears wrong by reporting a resilient double-digit growth profile in the EU. Read why GCT stock is ...

Energy Fuels has surged nearly 400% since last April, outperforming uranium and rare earth peers. Read why I retain a hold ...

SPDR Portfolio S&P 500 High Dividend ETF (SPYD) has outperformed SPY since June last year, challenging assumptions about ...

BeOne Medicines Q4 earnings and revenue beat the Street's expectations; the outlook missed by a small margin. Read why I have ...

Morgan Stanley Direct Lending Fund trades at a 27% NAV discount amid exaggerated SaaS sector fears. Check out why MSDL stock ...

SCZ ETF review: diversification and 2025 gains vs a 0.40% expense ratio, Japan concentration and currency risk.

Verisk Analytics' recent slump aligns with an industry-wide downturn, as evidenced by similar trends in Moody's and Experian.

Acadia Pharmaceuticals' two approved drugs, NUPLAZID and DAYBUE are guided to continue their strong growth trajectories. Read why ACAD stock is a buy.

Omnicom Group offers compelling value at under 8x earnings, with a well-covered 3.5% yield and significant upside potential.

Fidus Investment trades at a discount to NAV with resilient earnings and a $0.43 dividend covered by NII. See here for an ...

Momentum and liquidity support ECH, but above-average expenses and below-average yield challenge total returns. Check out why ...